Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.54 |
| ▸ | WNT3A | P56704 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455978 | 1.00 | CTNNB1 (0.54) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 | |
| Benzene SCHEMBL28069373 | 0.96 | MAOB (0.52) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 | |
| Oxirane SCHEMBL826781 | 0.92 | CTNNB1 (0.49) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL15504108 | 0.83 | DYRK1A (0.65) | CTNNB1WNT3ADYRK1ACA12CA2 | |
| SCHEMBL172445 | 0.81 | CYP2A6 (0.48) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL13305088 | 0.80 | CTNNB1 (0.40) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 | |
| Ethoxycarbonyl Group SCHEMBL28120407 | 0.80 | CTNNB1 (0.47) | CTNNB1WNT3ACYP2A6ALDH1A1DYRK1A | |
| SCHEMBL1602149 | 0.78 | HTR1B (0.55) | CTNNB1WNT3ACYP2A6DYRK1ACA12 | |
| SCHEMBL4851681 | 0.78 | CTNNB1 (0.49) | CTNNB1WNT3ACYP2A6DYRK1ACA12 | |
| SCHEMBL827503 | 0.76 | CYP2A6 (0.42) | CTNNB1WNT3ACYP2A6ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | claimed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | claimed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | claimed |
| EP-3082884-B1 | AIR CARE AND CLEANING PRODUCTS CONTAINING CNGA2 ANTAGONISTS | HENKEL AG & CO KGAA (DE) | 2018-02-28 | — | — | EP | claimed |
| EP-3083910-B1 | USE OF CNGA2 AGONISTS FOR ENHANCING THE OLFACTORY EFFECT OF AN ODORANT | HENKEL AG & CO KGAA (DE) | 2017-09-06 | — | — | EP | claimed |
| EP-3082884-A1 | AIR CARE AND CLEANING PRODUCTS CONTAINING CNGA2 ANTAGONISTS | Henkel AG & Co. KGaA (DE) | 2016-10-26 | — | — | EP | claimed |
| EP-3083910-A1 | USE OF CNGA2 AGONISTS FOR ENHANCING THE OLFACTORY EFFECT OF AN ODORANT | Henkel AG & Co. KGaA (DE) | 2016-10-26 | — | — | EP | claimed |
| US-20160289594-A1 | USE OF CNGA2 AGONISTS FOR ENHANCING THE OLFACTORY EFFECT OF AN ODORANT | HENKEL AG & CO. KGAA (DE) | 2016-10-06 | — | — | US | claimed |
| WO-2015091055-A1 | AIR CARE AND CLEANING PRODUCTS CONTAINING CNGA2 ANTAGONISTS | HENKEL AG & CO. KGAA (DE) | 2015-06-25 | — | — | WO | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | claimed |
| CN-101405002-A | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-08 | — | — | CN | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289594-A1 | USE OF CNGA2 AGONISTS FOR ENHANCING THE OLFACTORY EFFECT OF AN ODORANT | CNR2, OR51E2, CHRNA2 | CTNNB1 2683/4885WNT3A 2136/4885CYP2A6 2607/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | CTNNB1 1618/4885WNT3A 1674/4885CYP2A6 3337/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | CTNNB1 4213/4885WNT3A 2648/4885CYP2A6 3896/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | CTNNB1 4535/4885WNT3A 3341/4885CYP2A6 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.